Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...
HealthDay on MSN16h
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke SurvivorsFor patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...
Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...
The majority of patients may safely take glucagon-like peptide 1 receptor agonists (GLP-1 RAs) before elective surgery and ...
HealthDay on MSN2d
Expanding Access to Obesity Medications Could Avert 42,000 Deaths/YearExpanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could avert 42,000 deaths annually ...
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...
Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...
Hosted on MSN17h
SGLT-2 Inhibitors Beneficial for Patients With NephrolithiasisA total of 20,146 patients with nephrolithiasis and type 2 diabetes, including those with gout at baseline, initiated an SGLT ...
With the rising popularity of glucagon-like peptide-1 agents for treating obesity, many bariatric surgery programs across the ...
Lexaria Bioscience (LEXX) provides the following glucagon-like peptide-1 industry update. It is no surprise that Novo Nordisk’s ...
On October 3, Amy Kane, 35, who once weighed 300 pounds at her heaviest, garnered 1.7 million views (@amyinhalf) after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback